Disclosure of Interests: Dafne Capelusnik Speakers bureau: IMS, Grant/ research support from: Pfizer, Stizheng Steven Zha, None declared, Annelies Boonen: None declared, Nelly Ziaie Speakers bureau: Roche, Abbvie, Eli Lilly, Pfizer, Janssen, Novartis, Pierre Fabre, Apteox, Pharmaline. Paid instructor for: Abbvie, Eli Lilly, Sanofi-Aventis, Pfizer, Janssen, Consultant of: Roche, Abbvie, Eli Lilly, MSD, Novartis, UCBi, Consultant of: Abbvie, Lilly, MSD, Novartis, UCBi, Sanofi, Grant/research support from: MSD

DOI: 10.1136/annrheumdis-2021-eular.504

RESPONSIVENESS OF SPINAL MOBILITY MEASUREMENTS IN AXIAL SPONDYLOARTHRITIS USING CONVENTIONAL AND ADVANCED METROLOGY: A PILOT STUDY

J. L. Garrido-Castro1, I. C. Aranda-Valera2, P. Gardiner2, P. Machado2, J. Condeil1, C. Gonzalez-Navas1, E. Collantes Estevez2 On behalf of the iMaxSpA study group.

Background: Spinal mobility is an important outcome in axial spondyloarthritis (axSpA). Standardized metrology tests have been defined and validated. Nevertheless, conventional metrology measures lack responsiveness, particularly in the context of assessing short-term response to treatments. Advanced metrology devices have also been used in axSpA, namely optical motion capture systems (MoCap) and Inertial Measurement Systems (IMU). These systems have better psychometric properties in terms of accuracy and reliability for analysing spinal mobility.

Objectives: To compare the responsiveness of spinal mobility using conventional and advanced metrology.

Methods: Spinal mobility was measured using an IMU based system (ViMove©) with sensors located at: occiput and T3 for cervical mobility, L1 and sacrum for lumbar mobility, and T3 and sacrum for thoracic-lumbar mobility. A MoCap system (UCOTrack©) using 13 markers was also used to record the movements in 3 planes (flexion+extension, rotation, and lateral flexion). The UCOASM© [1] index was calculated using measures obtained by MoCap and by the IMU system. Other metrology indexes based on IMU measures developed by the authors [2] were also calculated. Patients were assessed before (PRE) and 3 months after (POST) TNF blocker treatment. The Wilcoxon signed-rank test was used to test differences between pairs of pre- and post-treatment. Cohen’s d was used for calculating the effect size of improvement.

Results: 12 axSpA patients were recruited from the CASTRO cohort (42% female, age 46±11 years, disease duration 16±13 years). Results PRE and POST are shown in Table 1: means (sd), statistical significance, and effect size. Disease activity and functional indexes were lower in POST and these differences were significant, especially in ASDAS. Conventional metrology lacked responsiveness, except for cervical rotation. MoCap showed moderate responsiveness in cervical rotation, in thoracolumbar mobility and with regards to the UCOASM. Using IMU measures, responsiveness was good in terms of cervical flexion and rotation. For Lumbar (L_) and Lumbar Thoracic (LT_), lateral flexion shown significant improvement and lumbar rotation shown the best responsiveness.

Conclusion: Conventional metrology lacks short-term responsiveness. Advanced metrology using MoCap and IMU showed, in this pilot study, better responsiveness compared to conventional measures. Furthermore, IMU provide a feasibility similar to conventional metrology, and could be easily implemented in the context of clinical trials and observational studies.

REFERENCES:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.562

PERIPHERAL ARTHRITIS AND HIGHER DISEASE ACTIVITY LEAD TO MORE FUNCTIONAL IMPAIRMENT IN AXIAL SPONDYLOARTHRITIS: LONGITUDINAL ANALYSIS FROM ESPAXIA

D. Capelusnik1, S. Ramiro2,3, E. E. Schneeberger1, G. Citera1. Instituto de Rehabilitación Psicosocial, Rheumatology, CABA, Argentina; 2Leiden University Medical Centre, Rheumatology, Leiden, Netherlands; 3;Zuyderland Medical Centre, Rheumatology, Heerlen, Netherlands

Background: Preserving functional ability is among the main goals when treating patients with axSpA. Higher disease activity, reduced axial mobility, and increased spinal radiographic damage, and smoking status have shown to be longitudinally associated with functional worsening. The presence of peripheral arthritis has also been associated with worse functional ability during follow-up, though not in a true longitudinal analysis.

Objectives: To investigate whether peripheral arthritis together with disease activity independently contribute to functional impairment over time in patients with axSpA and to evaluate if there are contextual factors modifying this relationship.

Methods: Patients with axSpA from the ESPAXIA cohort were followed-up annually over 7 years. Physical function was assessed by the self-reported questionnaire BASFI, disease activity by ASDAS and peripheral arthritis was also recorded. The association between BASFI (outcome), peripheral arthritis and ASDAS (main variables of interest) over time was tested in generalized estimating equations (GEE) models. Models were autoregressive, i.e. adjusted for BASFI 1 year earlier, to allow for a truly longitudinal interpretation. Interactions between each of ASDAS and peripheral arthritis with contextual factors were tested.

Results: 185 patients were included (77 % male, mean age 42 (SD 13), mean disease duration 9.4 (SD 9.6) years. Mean baseline ASDAS was 2.3 (1.4), mean BASFI

740

Scientific Abstracts